Evaluation of risk factors associated with drug-resistant tuberculosis in Yemen: data from centres with high drug resistance

Ammar Ali Saleh Jaber 1,2* and Baharudin Ibrahim 1

Abstract

Background: The World Health Organization (WHO) has reported that Yemen has a high burden of drug resistance and a worrying shortage of implemented diagnostic methods and drug treatment regimens. Therefore, in this study, we evaluated the risk factors associated with multidrug-resistant tuberculosis (MDR-TB) and explored the poor TB management in Yemen.

Methods: Between January 2014 and December 2016, we enrolled 135 patients with MDR-TB from drug resistance programmes at four major TB centres in Yemen for this prospective study. After exclusion of 20 patients, treatment outcomes were reported for 115 patients who attended a series of follow-ups.

Results: A total of 115 patients with MDR-TB were analysed from the four main TB centres in Yemen. Most patients (35.2%) were from the Aden TB centre. A success rate of 77.4% was reported for TB treatment. Of the 115 patients, 69.6% were resistant to two drugs, 18.3% were resistant to three drugs, and 12.2% were resistant to four drugs. During the intensive phase of treatment, 19 patients (16.5%) reported one or more adverse events. A multivariate logistic regression analysis revealed that a baseline body weight of ≤40 kg (p = 0.016; adjusted odds ratio (AOR) = 25.09), comorbidity (p = 0.049; AOR = 4.73), baseline lung cavities (p = 0.004; AOR = 15.32), and positive culture at the end of the intensive phase (p = 0.009; AOR = 8.83) were associated with the unsuccessful treatment outcomes in drug-resistant TB patients.

Conclusions: The success rate achieved after treatment was below the levels established by the WHO End TB Strategy (90%) and the United Nations Sustainable Development Goals (80%). Identification of risk factors associated with MDR-TB in Yemen is essential because it allows health workers to identify high-risk patients, especially in the absence of a second-line treatment or a laboratory diagnostic method. The Yemen National Tuberculosis Control Program should formulate new strategies for early detection of MDR-TB and invest in new programmes for MDR-TB management.

Keywords: Drug resistance, Khat, Tuberculosis, Yemen
Among new cases, the success rate of treatment was 85%, and among previous patients, it was 75%; a low success rate (72%) was achieved with rifampicin and in patients with MDR-TB [5]. Only one survey was conducted in Yemen to determine the prevalence of MDR-TB in 2004. The study reported that 14 of 511 (2.7%) newly treated and seven of 54 (12.9%) previously treated patients had MDR-TB [6].

Factors such as limited availability of free and second-line drugs in developing countries such as Yemen, a prolonged duration of treatment, high prices, treatment-associated toxicity, the lack of specialists and laboratory facilities, and the practice of selling second-line TB drugs in private sectors hinder the effective characterisation of treatment outcomes of drug resistance therapy [7–11]. Because of the civil war in Yemen, conditions have recently worsened, and information regarding MDR-TB is scarce. Moreover, treatment outcomes and disease management have not been explored in this country. In this study, we aimed to evaluate the risk factors associated with MDR-TB and to explore the poor TB management in Yemen. The current study is, therefore, the first to report treatment outcomes of MDR-TB in Yemen and its associated risk factors.

**Methods**

**Study population**

This prospective observational study was conducted in four major TB centres, namely Al-Hudaydah, Taiz, Aden, and Sana’a, which are among the largest in Yemen. Only TB culture is performed in these centres for diagnosis. A total of 135 patients with MDR-TB were enrolled between 01 January 2014 and 31 December 2016 (Fig. 1). Most of the MDR-TB patients (115) had follow-up visits until treatment outcomes were reported. Patients who were younger than 18 years and polyresistant (resistant to more than one first-line anti-TB drug, other than isoniazid and rifampicin), as well as those who refused to participate, were excluded from the study.

**Fig. 1** Flowchart of the number of MDR-TB patients enrolled in the study
The study was approved by the Yemen Ministry of Public Health and National Tuberculosis Control Program (NTCP).

Bacteriology and drug susceptibility testing
The drug-resistant TB suspects referred to the study site were initially evaluated using two sputum samples. After positive direct sputum smear microscopy for acid-fast bacilli (AFB) using Ziehl–Neelsen staining and rapid testing for *Mycobacterium tuberculosis* and rifampicin resistance using the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), sputum samples were sent to the Sana’a TB centre laboratory for sputum culture and drug susceptibility testing (DST). DST is only available at the main TB centre in Yemen, which is located in Sana’a. DST was performed at baseline and repeated whenever deemed necessary; AFB sputum smear and culture were performed every month.

Treatment of multidrug-resistant TB in Yemen
Based on the guideline for MDR management in Yemen, MDR-TB treatment is under category 3 [1]. The bacteriological examination of MDR-TB includes sputum microscopy and culture. To confirm TB, we performed sputum microscopy at the beginning of treatment based on the infectiousness. At least one sputum sample for smear and culture was collected at the start of each treatment. To consider MDR-TB under category 3, at least one pretreatment culture or smear must be positive. Collection of samples for culturing or smearing was performed less than 30 days before or 7 days after the initiation of the categorical treatment. AFB sputum smears and cultures were used to monitor patients on a monthly basis throughout the therapy period.

Data collection
The sociodemographics of the patients, laboratory test results, and clinical data were obtained using a standardised data collection form. Information regarding adverse effect was obtained from drug-resistant patients, patients’ treatment cards, and TB centre records. Sputum conversion results were obtained from the laboratories of the TB centres. Each patient had a unique code for follow-up laboratory tests.

Treatment outcomes
Final treatment outcomes were classified into two categories (successful or unsuccessful). Successful treatment outcomes were further reported as either ‘cured’ or ‘completed’. Unsuccessful treatment outcomes were reported when patients experienced treatment failure, died during treatment from any cause, were lost to follow-up, or were not evaluated.

Statistical analysis
Data were analysed using the PASW software version 24 (IBM Corp, Armonk, NY, USA). All categorical data were reported as a percentage and number. Univariate logistic regression was used to identify the risk factors associated with unfavourable treatment outcomes. Significant values were added to multivariate logistic regression to determine the final risk factors. Significance was defined as a *p*-value of less than 0.05. Odds ratio (OR), adjusted odds ratio (AOR), and confidence interval were also calculated.

Results

Treatment regimens for MDR-TB patients in Yemen
Treatment for MDR-TB in Yemen lasts for at least 20 months after culture conversion, but an extension to 24 months may be indicated for patients with extensive pulmonary damage. Table 1 lists the treatment regimens used in Yemen.

Patient characteristics
Of the 135 MDR-TB patients initially registered at the four main TB centres in Yemen, only 115 fulfilled the inclusion criteria and were thus included in the final analysis (Fig. 1). Sixty-five (56.5%) of the patients were males, and 35.7% of the patients were from the Aden TB centre. Additionally, 60.9% (70) of the patients were of reproductive age (≤45 years), and 73% (84) were married. Although the study was conducted in an urban area, approximately 40% (46) of patients travelled from rural areas. Most patients (104, or 90.4%) chewed khat, and 73.9% (85) were smokers. Approximately 73% (84) of the patients lived under the poverty line as their monthly income was less than 50% of the threshold. Illiteracy was found to be high (67%), and 5.2% (6) of the patients had previously received TB treatment, while 94.8% (109) were newly diagnosed. During the intensive phase of treatment, 26.1% (30) of patients experienced adverse effects, and 12.2% (14) changed their treatment regimens because of adverse effects (Table 2).

Treatment outcomes
At treatment completion, the success rate was 77.4% (29.6% cured and 47.8% completed), while unsuccessful treatment outcomes were indicated for 22.6% of patients. Out of the total (115) patients, 14 (12.2%) died, six (5.2%) were lost to follow-up, four (3.5%) experienced treatment failure, and data from two patients (1.7%) were not evaluated (Table 3).

Clinical outcome-related patient characteristics
Table 4 shows the clinical characteristics of patients with MDR-TB. Approximately 59.1% had a high sputum grade at the beginning of treatment, and 40.9% displayed
baseline lung cavities. Moreover, 41.1% reported sputum conversion at the end of the second month of treatment, and 59.1% of the patients had haemoglobin levels below normal. Thirty patients (26.1%) also had comorbidities, including 12 patients with diabetes, eight with hypertension, five with HIV infection, and two with chronic obstructive pulmonary disease.

Resistance patterns
Most of the patients (69.6%) were resistant to two drugs, while 21 (18.3%) patients were resistant to three drugs and 14 (12.2%) patients were resistant to four drugs (Table 4).

Adverse events during the intensive phase
Nineteen patients (26.1%) experienced one or more adverse events during the intensive phase of treatment, with gastrointestinal effects (13.3%) being the most dominant. Approximately 6.7% of patients reported arthralgia, hearing disturbance, hepatic toxicity, and haematological reactions, and 3.3% reported psychiatric disorders, renal toxicity, peripheral toxicity, and dermatological reactions (Table 5).

Predictors of unsuccessful treatment outcomes
Univariate analysis revealed that a baseline body weight of ≤40 kg (p = 0.031; OR = 4.1), comorbidity (p = 0.044; OR = 18.8), baseline lung cavities (p = 0.036; OR = 17.9), and positive culture at the end of the intensive phase of treatment (p = 0.009; AOR = 8.83) were also found to be associated with unsuccessful treatment outcomes in the MDR-TB patients (Table 7).

Discussion
At the end of the treatment period, only 89 (77.4%) of the 115 patients achieved success, and thus, this study did not reach the success rate established by the United Nations Sustainable Development Goals (80%) and the WHO End TB Strategy (90%). The low success rate in the present study was due to a high mortality rate (12.2%) and loss to follow-up (5.2%). The high mortality rate in our study might have been due to various factors, such as the late detection of MDR-TB and the disease, late initiation of the treatment course, a low educational level, a high number of previous TB episodes, the presence of comorbid conditions, especially diabetes mellitus, insufficient treatment, and unavailability of modern laboratory equipment for detecting resistance to other second-line TB drugs [12]. Nine countries (Afghanistan, Burkina Faso, Chad, Congo, Papua New Guinea, Sierra Leone, Somalia, South Sudan, and Yemen), with more than 5000 TB cases registered in 2015, reported that they did not have the capability to perform phenotypic DST [13], and similar studies have reported high mortality rates in the Dominican Republic and Russia (11.3 and 10.9%, respectively) [14, 15]. The NTCP should therefore formulate new strategies for early detection of MDR-TB and invest in new treatments for MDR-TB management. Based on the literature, approximately 26% of patients are lost to follow-up because of drug toxicity. Other factors include poor knowledge/understanding of MDR-TB, high levels of poverty, a low economic status, low family support, and unsatisfactory health services available at main centres [16–18]. To improve the TB healthcare system in Yemen, the following measures should be adopted: the provision of adequate training for health care providers and counselling for patients, retrieval of the exact address for the parents of patients, establishment of a proper drug supply, provision of free food and transportation for patients and caregivers, dissemination of health educational materials by health workers, and initiation of home visits to eliminate the lost to follow-up treatment outcome.

In the present study, a baseline body weight of ≤40 kg was associated with unsuccessful treatment outcomes, which is consistent with the data of other studies [19–21]. Body mass index is considered an accurate measure for determining whether a patient is underweight. However, since patient height was not measured, this parameter could not be determined. Most of the population in Yemen is below the poverty line [22], earning an income below 50 US dollars per month [23]. Therefore, patients have a low body weight, which can be associated with low

Table 1 Treatment regimens for MDR-TB patients in Yemen

| Resistance to | Treatment regimen |
|--------------|-------------------|
| RHSE         | Regimen 1: 8 months of amikacin + levofloxacin + ethionamide + cycloserine + para-aminosalicylic acid, followed by 16 months of levofloxacin + ethionamide + cycloserine + para-aminosalicylic acid |
| RHS          | Regimen 2: 8 months of amikacin + levofloxacin + ethionamide + cycloserine + pyrazinamide, followed by 16 months of levofloxacin + ethionamide + cycloserine + pyrazinamide |
| RH           | Regimen 3: 8 months of amikacin + levofloxacin + ethionamide + cycloserine + ethambutol, followed by 16 months of levofloxacin + ethionamide + cycloserine + ethambutol |

Abbreviations: R, rifampicin; H, isoniazid; S, streptomycin; E, ethambutol
immunity, and this can lead to TB displaying longer than usual manifestations in these patients [20]. Initiating food programmes for MDR-TB patients may increase their weight, consequently improving their immunity and the success rate of treatment.

This study showed baseline cavitation to be a risk factor associated with unsuccessful treatment outcomes, which may be due to a low efficacy of anti-TB drugs. Lung cavitation at baseline is a poor predictor of treatment outcome [14, 18, 19, 24]. In the present study, a regimen modification due to a severe adverse event was reported for 12.2% of patients, which was lower than the

| Table 2 Characteristics of the MDR-TB patients (N = 115) |
|--------------------------------------------------------|
| Characteristics                                      | Patients, N (%) |
| Centre                                                |               |
| Al-Hudaydah                                          | 37 (32.2)     |
| Taiz                                                  | 17 (14.8)     |
| Sana'a                                                | 20 (17.4)     |
| Aden                                                  | 41 (35.7)     |
| Sex                                                   |               |
| Male                                                  | 65 (56.5)     |
| Female                                                | 50 (43.5)     |
| Age (years)                                           |               |
| ≤ 45                                                  | 70 (60.9)     |
| > 45                                                  | 45 (39.1)     |
| Marital status                                        |               |
| Married                                               | 84 (73)       |
| Unmarried                                             | 31 (27)       |
| Area                                                  |               |
| Rural                                                 | 46 (40)       |
| Urban                                                 | 69 (60)       |
| Household size                                        |               |
| ≤ 7                                                   | 40 (34.8)     |
| > 7                                                   | 75 (65.2)     |
| Smoking status                                        |               |
| Non-smoker                                            | 30 (26.1)     |
| Smoker                                                | 85 (73.9)     |
| Chewing khat<sup>a</sup>                               |               |
| Yes                                                   | 104 (90.4)    |
| No                                                    | 11 (9.6)      |
| Literacy status                                       |               |
| Illiterate                                            | 77 (67)       |
| Literate                                              | 38 (33)       |
| Employment status                                     |               |
| Employed                                              | 31 (27)       |
| Unemployed                                            | 84 (73)       |
| Monthly income (rials<sup>b</sup>)                    |               |
| ≤ 10,000                                              | 31 (27)       |
| > 10,000                                              | 84 (73)       |
| Baseline weight (kg)                                  |               |
| ≤ 40                                                  | 36 (31.3)     |
| > 40                                                  | 79 (68.7)     |
| BCG vaccination<sup>c</sup>                           |               |
| No                                                    | 21 (18.3)     |
| Yes                                                   | 94 (81.7)     |
| History of TB treatment                               |               |
| Previously treated                                    | 6 (5.2)       |
| Newly treated                                         | 109 (94.8)    |

<sup>a</sup>Khat is a shrub that grows in parts of East Africa and Yemen

<sup>b</sup>Rial, one dollar is equivalent to approximately 215 rials

<sup>c</sup>Bacillus Calmette–Guerin (BCG) is a vaccine for TB

immunity, and this can lead to TB displaying longer than usual manifestations in these patients [20]. Initiating food programmes for MDR-TB patients may increase their weight, consequently improving their immunity and the success rate of treatment.

This study showed baseline cavitation to be a risk factor associated with unsuccessful treatment outcomes, which may be due to a low efficacy of anti-TB drugs. Lung cavitation at baseline is a poor predictor of treatment outcome [14, 18, 19, 24]. In the present study, a regimen modification due to a severe adverse event was reported for 12.2% of patients, which was lower than the

| Table 3 Treatment outcomes in the MDR-TB patients based on the WHO/International Union Against Tuberculosis and Lung Disease criteria |
|----------------------------------------------------------------------------------------------------------------------------|
| Treatment outcome                                      | Patients, N (%) |
| Successful                                             | 89 (77.4)       |
| Cured                                                  | 34 (29.6)       |
| Completed                                              | 55 (47.8)       |
| Unsuccessful                                           | 26 (22.6)       |
| Lost to follow-up                                      | 6 (5.2)         |
| Not evaluated                                          | 2 (1.7)         |
| Died                                                    | 14 (12.2)       |
| Failed                                                  | 4 (3.5)         |
| Total                                                   | 115 (100)       |
percentages (47 and 45% of patients) reported in Iran and Latvia, respectively [25, 26]. As reported, MDR-TB regimen modifications are predictors of unsuccessful treatment outcomes [26]. Low bioavailability of a second-line drug, which is considered less potent than first-line drugs, may be the reason for the association between regimen modification and unfavourable treatment outcome [26]. This important finding suggests that early detection and management of adverse effects may improve treatment outcomes [25].

In this study, comorbidities, predominantly diabetes mellitus, were also found to be a risk factor associated with unsuccessful treatment outcomes. Similar studies have also reported diabetes mellitus as a risk factor for these patients [12, 27]. Diabetes mellitus lowers one’s immunity, thereby increasing the strength of TB infection and reducing the effectiveness of a TB drug. Moreover, the complex medication schedule for diabetes and TB may lead to low adherence of patients to the schedule [12]. Early detection and management of comorbid conditions, especially diabetes mellitus, may therefore improve the outcomes of these patients.

Negative culture at the end of the second month of MDR-TB treatment indicates the high effectiveness of a TB drug and is an early sign of successful treatment [28]. Various studies have reported a high success rate for those who achieved negative culture at the end of the second month of treatment [18, 24]. Our study reported positive sputum cultures after the second month of treatment, indicating an unsuccessful treatment outcome, similar to the data of some other studies [14, 18, 29, 30]. Based on this result, obtaining a positive culture at the end of the second month of treatment may help health workers identify TB patients with potentially unsuccessful outcomes. This variable can also act as a reliable indicator of treatment efficacy.

This study had some limitations. The study was conducted in four main TB centres in Yemen, with its major limitation being a small number of participating patients. Given, however, that this study included patients from an extensive geographical area, the findings may reflect

| Variable                  | Patients, N (%) |
|---------------------------|-----------------|
| Sputum grading            |                 |
| Low                       | 47 (40.9)       |
| High                      | 68 (59.1)       |
| Baseline lung cavity      |                 |
| No                        | 68 (59.1)       |
| Yes                       | 47 (40.9)       |
| Positive culture at the end of the second month | | |
| No                        | 67 (58.3)       |
| Yes                       | 48 (41.7)       |
| Creatinine level          |                 |
| Normal                   | 105 (91.3)      |
| Above normal              | 10 (8.7)        |
| Hb level                  |                 |
| Normal                   | 47 (40.9)       |
| Below normal              | 68 (59.1)       |
| WBC count                 |                 |
| Normal                   | 78 (67.8)       |
| Above normal              | 37 (32.2)       |
| Bilirubin level           |                 |
| Normal                   | 106 (92.2)      |
| Above normal              | 9 (7.8)         |
| Comorbidity               |                 |
| No                       | 85 (73.9)       |
| Yes                      | 30 (26.1)       |
| Type of comorbidity       |                 |
| Diabetes mellitus         | 12 (40)         |
| Hepatitis                 | 3 (10)          |
| Hypertension              | 8 (26.7)        |
| Chronic obstructive       | 2 (6.7)         |
| pulmonary disease         |                 |
| HIV                       | 5 (16.6)        |
| Resistance to TB drugs    |                 |
| HR                        | 80 (69.6)       |
| HRE                       | 11 (9.6)        |
| HRS                       | 10 (8.7)        |
| HRES                      | 14 (12.1)       |

*Normal ranges: Hb > 13 g/dL (males) and > 11.5 g/dL (females); WBCs > 11,000/mm³; creatinine < 1.1 mg/dL (males) and < 0.9 mg/dL (females); bilirubin <1 mg/dL

Abbreviations: Hb, haemoglobin; WBC, white blood cell; H, isoniazid; R, rifampicin; E, ethambutol; S, streptomycin

Table 4 Clinical characteristics and drug resistance patterns of the patients (N = 115)
the treatment outcomes of MDR-TB and the associated risk factors across Yemen. Nonetheless, a multi-centre study with a large sample size and drug-susceptible TB controls is needed to corroborate the findings.

**Conclusions**

By knowing the risk factors associated with unfavourable treatment outcomes, health workers can easily identify patients with a high risk of death or those who are likely to be lost to follow-up during treatment. The clinical outcomes and clinical management of MDR-TB can therefore be improved by considering these factors. Initiating new food programmes may increase the body weight and immunity of patients, while establishing new strategies for identifying and managing diabetes may increase their immunity.

The NTCP should formulate new strategies for early detection of MDR-TB and invest in new programmes for

| Table 6 Predictors of unsuccessful treatment outcomes, as determined by simple logistic regression |
|-----------------------------------------------|
| Variable | Treatment outcome | β | SE | p-Value* | OR (95% CI) |
|----------|-------------------|---|----|----------|-------------|
| **Age (years)** | | | | | |
| ≤ 45 | 8 | 62 | Ref | | |
| > 45 | 18 | 27 | 0.722 | 1.52 | 0.636 | 0.486 (0.24–9.7) |
| **Baseline weight (kg)** | | | | | |
| > 40 | 13 | 23 | Ref | | |
| ≤ 40 | 13 | 66 | 3.83 | 1.77 | 0.031 | 4.1 (1.43–14.8) |
| **Comorbidity** | | | | | |
| No | 7 | 78 | Ref | | |
| Yes | 19 | 11 | 2.939 | 1.461 | 0.044 | 18.8 (1.01–33.7) |
| **Baseline lung cavities** | | | | | |
| No | 2 | 66 | Ref | | |
| Yes | 23 | 24 | 2.889 | 1.377 | 0.036 | 17.9 (1.20–26.7) |
| **Creatinine level** | | | | | |
| Normal | 17 | 88 | Ref | | |
| Above normal | 1 | 9 | −0.347 | 1.11 | 0.75 | 0.71 (0.081–6.2) |
| **History of streptomycin use** | | | | | |
| No | 18 | 74 | Ref | | |
| Yes | 8 | 15 | 1.99 | 1.210 | 0.100 | 7.3 (0.68–78) |
| **Positive culture, end of I.P.** | | | | | |
| No | 64 | 3 | Ref | | |
| Yes | 25 | 23 | 2.667 | 1.112 | 0.016 | 14 (1.62–127) |
| **History of failed TB treatment** | | | | | |
| No | 5 | 58 | Ref | | |
| Yes | 21 | 31 | 1.174 | 0.975 | 0.229 | 3.23 (0.47–21.8) |
| **Smoking status** | | | | | |
| No | 1 | 29 | Ref | | |
| Yes | 25 | 60 | 1.757 | 1.55 | 0.259 | 3.2 (0.47–21.87) |
| **Chewing khat** | | | | | |
| No | 2 | 9 | Ref | | |
| Yes | 24 | 80 | −0.806 | 2.043 | 0.693 | 0.4 (0.008–24.5) |
| **Resistance to FLDs** | | | | | |
| ≤ 2 | 17 | 60 | Ref | | |
| > 2 | 9 | 29 | −1.11 | 0.898 | 0.215 | 0.3 (0.05–1.911) |

*p-Values ≤0.05 are shown in bold

Khat is a shrub that grows in parts of East Africa and Yemen

Abbreviations: SE, standard error of the mean; OR, odds ratio; CI, confidence interval; Ref, reference group; I.P., intensive phase; FLD, first-line drug
Table 7 Predictors of unsuccessful treatment outcomes, as determined by multiple logistic regression

| Variable                  | β   | SE  | p-Value | AOR   | 95% CI          |
|---------------------------|-----|-----|---------|-------|-----------------|
| Comorbidity               | 1.556 | 0.790 | 0.049 | 4.73  | 1.00–22.30      |
| Baseline lung cavities    | 2.729 | 0.935 | 0.004 | 15.32 | 2.45–95.8       |
| Baseline weight ≤ 40 kg   | 3.223 | 1.344 | 0.016 | 25.09 | 1.80–349        |
| Positive culture, end of I. | 2.178 | 0.830 | 0.009 | 8.83  | 1.73–44.9       |

Abbreviations: SE, standard error of the mean; AOR, adjusted odds ratio; CI, confidence interval; I.p., intensive phase

MDR-TB management. Early detection of adverse effects of TB drugs allows drug regimen modification during treatment, which in turn improves patient outcomes.

Despite their extensive efforts, health workers and the NTCP in Yemen have had little success in improving the treatment outcomes of patients with MDR-TB. We believe that the success rate of TB treatment in Yemen may decrease even further because of the instability caused by the current war. Since treatment was reported to be unavailable, non-governmental organisations must increase their efforts to fulfil this void for the prevention of future disasters.

Acknowledgements
We would like to thank all health workers at the Taiz and Alhoudidah Centres for the opportunity to conduct the study. We also extend our appreciation to Universiti Sains Malaysia for the possibility to conduct this study and thank the Yemen Health Ministry and National Tuberculosis Control Program for approving our work and collaborating with us. Finally, we would like to thank our supervisors for their constructive comments throughout the research activities.

Funding
This work did not receive any funding.

Availability of data and materials
The datasets used in this study are available from the corresponding author upon reasonable request.

Authors’ contributions
BI wrote the proposal and performed follow-ups at all stages of data collection. AASJ participated in data collection, analysed the data, and wrote the manuscript. Both authors read and approved the final manuscript.

Ethics approval and consent to participate
Although the study did not include human samples, patient cards and records were reviewed for data collection. Therefore, consent for participation was designed by the investigators and approved by the ethical committee of records were reviewed for data collection. Therefore, consent for participation

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 28 January 2019 Accepted: 7 May 2019
Published online: 24 May 2019

References
1. World Health Organization: companion handbook to the WHO guidelines for the programmatic management of drug-resistance tuberculosis. https://www.who.int/tb/publications/pmdt_companionhandbook/en/ (2014). Accessed 08 May 2018.
2. Ahmad N, Javaid A, Basit A, Afzdi AK, Khan MA, Ahmad I, et al. Management and treatment outcomes of MMDR-TB: results from a setting with high rates of drug resistance. Int J Tuberc Lung Dis. 2015;19:1109–14.
3. National Tuberculosis Control Programme: treatment of tuberculosis guidelines, (2010). Accessed 09 Apr 2018.
4. World Health Organization: Guideline on management of drug resistance-TB, In WHO treatment guidelines for drug-resistant tuberculosis, (2016). Accessed 06 Apr 2018.
5. Ahmad S, Mokaddas E, Al-Mutairi NM. Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East region. Expert Rev Anti-Infect Ther. 2018;16:709–21.
6. Al-Akhali A, Okhado A, Fujihi A, Mitalai S, Yamada N, Masui T, et al. Nationwide survey on the prevalence of anti-tuberculosis drug resistance in the Republic of Yemen, 2004. Int J Tuberc Lung Dis. 2007;11:1328–33.
7. Ahmed MM, Velayati AA, Mohammed SH. Epidemiology of multidrug-resistant, extensively drug resistant, and totally drug resistant tuberculosis in the Middle East countries. Int J Mycobacteriol. 2016;5:249–56.
8. Zigmol M, Hosseini MS, Wright A, Weezenbeek C, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Invest Dermatol. 2006;194:675–85.
9. National Tuberculosis Control Programme: Guideline on management of drug resistance-TB Yemen, (2012). Accessed 02 Nov 2018.
10. Chee CBE, Boudville IC, Chan SP, Zee YK, Wang YT. Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit—a one-year retrospective survey. Int J Tuberc Lung Dis. 2000;4:496–503.
11. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, et al. MDR tuberculosis—critical steps for prevention and control. N Engl J Med. 2010;363:1050–8.
12. Kang YA, Kim SY, Jo KW, Kim HJ, Park SK, Kim TH, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiraion. 2014;86(6):472–82.
13. World Health Organization: Global tuberculosis report 2016, (2016). Accessed 12 Jan 2016.
14. Rodríguez M, Monedero I, Caminero JA, Encarnación M, Dominguez Y, Acosta J, et al. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2015;19:1109–14.
15. Shu SS, Pasechnikov AD, Gémanova IF, Peremtin GG, Sreles AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDMR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10:402–8.
16. World Health Organization: Strategic plan for the prevention and control of multidrug-resistant and extensively drug-resistant tuberculosis in the Eastern Mediterranean Region (2010–2015), (2010). Accessed 23 July 2018.
17. Kiliman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33:1085–94.
18. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117:744–51.
19. Tang S, Tan S, Yao L, Li F, Guo X, Liu Y, et al. Risk factors for poor treatment outcomes in patients with MMDR-TB and XMDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8:1–8.
20. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914.
21. Ali A, Jaber S. Evaluation of tuberculosis defaulters in Yemen from the perspective of health care service. J Pharm Health Serv Res. 2018;9:1–12.

22. Jaber AAS, Khan AH, Sulaiman SAS, Ahmad N, Anaam MS. Evaluation of health-related quality of life among tuberculosis patients in two cities in Yemen. PLoS One. 2016;11:e0156258.

23. Jaber AAS, Khan AH, Sulaiman SAS. Evaluating treatment outcomes and durations among cases of smear-positive pulmonary tuberculosis in Yemen: a prospective follow-up study. J Pharm Policy Pract. 2017;10:36.

24. Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92:397–403.

25. Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirzaeidi M, Amiri MV, et al. Outcome of treatment of MMDR-TB patients with standardised regimens, Iran, 2002–2006. Int J Tuberc Lung Dis. 2008;12:750–5.

26. Bloss E, Kukša L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis. 2010;14:275–81.

27. Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XMDR-TB among treatment failures. PLoS One. 2007;2:e1126.

28. Qazi F, Khan U, Khawaja S, Javaid M, Ahmed A, Salahuddin N, et al. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis. 2011;15:1556–9.

29. Singla R, Osman MA, Khan N, Al-Sharif N, Al-Sayegh MO, Shaikh MA. Factors predicting persistent sputum smear positivity among pulmonary tuberculosis patients 2 months after treatment. Int J Tuberc Lung Dis. 2003;7:58–64.

30. Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014;59:1364–74.